Literature DB >> 1588150

Prevention of Haemophilus influenzae type b infections in Apache and Navajo children.

M Santosham1, B Rivin, M Wolff, R Reid, W Newcomer, G W Letson, J Almeido-Hill, C Thompson, G R Siber.   

Abstract

Prospective surveillance of Haemophilus influenzae type b (Hib) disease has been done since 1981 in two high-risk populations, White Mountain Apaches and Navajos. The attack rate in children less than 5 years of age is 5-10 times higher than in the general US population. Three vaccines were evaluated. Unconjugated Hib capsular polysaccharide produced lower antibody responses in 18- and 24-month-old Apache infants than in white infants. HbOC (Hib oligosaccharide covalently linked to the nontoxic mutant diphtheria toxin CRM197) produced low antibody responses in Navajo infants after one or two doses but induced responses similar to those in whites after three doses. The responses of 18-month-old Navajos to HbOC were lower than those of whites, but most achieved protective levels. PRP-OMP (Hib capsular polysaccharide linked to the outer membrane protein complex of Neisseria meningitidis) produced good immune responses in 2-month-old Navajo and Apache infants after a single dose. This vaccine was greater than 90% efficacious in protecting Navajo infants from Hib disease when given at 2 and 4 months of age. Even a single dose achieved a high protective efficacy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1588150     DOI: 10.1093/infdis/165-supplement_1-s144

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Why blacks do not take part in HIV vaccine trials.

Authors:  Demetrius L Moutsiakis; P Nancy Chin
Journal:  J Natl Med Assoc       Date:  2007-03       Impact factor: 1.798

2.  The epidemiology of Haemophilus influenzae type b disease in the Republic of Ireland.

Authors:  J Fogarty; A C Moloney; J B Newell
Journal:  Epidemiol Infect       Date:  1995-06       Impact factor: 2.451

3.  Respiratory disease in Canadian First Nations and Inuit children.

Authors:  Thomas Kovesi
Journal:  Paediatr Child Health       Date:  2012-08       Impact factor: 2.253

Review 4.  Vaccine immunogenetics: bedside to bench to population.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-07-01       Impact factor: 3.641

5.  Murine immune responses to Neisseria meningitidis group C capsular polysaccharide and a thymus-dependent toxoid conjugate vaccine.

Authors:  L J Rubinstein; P A García-Ojeda; F Michon; H J Jennings; K E Stein
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

6.  Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.

Authors:  G M Ginsberg; I Kassis; R Dagan
Journal:  J Epidemiol Community Health       Date:  1993-12       Impact factor: 3.710

Review 7.  Personalized vaccines: the emerging field of vaccinomics.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Expert Opin Biol Ther       Date:  2008-11       Impact factor: 4.388

Review 8.  Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics.

Authors:  Gregory A Poland; Robert M Jacobson; Inna G Ovsyannikova
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

9.  Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.

Authors:  T Barington; A Gyhrs; K Kristensen; C Heilmann
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  A defective Vkappa A2 allele in Navajos which may play a role in increased susceptibility to haemophilus influenzae type b disease.

Authors:  A J Feeney; M J Atkinson; M J Cowan; G Escuro; G Lugo
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.